Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active .beta.3 agonist by the use of the same
CA 2362070 A1 · Owner: Inoue, Kenji · Inventors: Inoue, Kenji; Mitsuda, Masaru; Taoka, Naoaki
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
An industrially useful process for preparing safely and efficiently intermediates for optically active .beta.3 adrenergic receptor agonist from easily available raw materials, which comprises reducing a substituted acetylpyridine derivative represented by general formula (9) enantioselectively into an optically active hydroxyethylpyridine derivative represented by general formula (10) (wherein * represents an asymmetric carbon atom), and converting this derivative into an intermediate for optically active .beta.3 adrenergic receptor agonist e.g. an optically active , dihydroxyethylpyridine derivative represented by general formula (14) or an optically active oxirane derivative …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 16, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 16, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 16, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.